Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OSIMERTINIB vs RIBOCICLIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OSIMERTINIB vs RIBOCICLIB: Safety Overview

Metric OSIMERTINIB RIBOCICLIB
Total FAERS Reports 27,750 27,997
Deaths Reported 12,456 4,501
Death Rate 44.9% 16.1%
Hospitalizations 5,277 6,700
Average Patient Age 68.2 yrs 60.2 yrs
% Female Patients 66.0% 99.0%
FDA Approval Date Nov 13, 2015 Mar 13, 2017
Manufacturer AstraZeneca Pharmaceuticals LP Novartis Pharmaceuticals Corporation
Route ORAL ORAL
Marketing Status Prescription Prescription